TITLE

CORRECTION

PUB. DATE
February 2008
SOURCE
Mayo Clinic Proceedings;Feb2008, Vol. 83 Issue 2, p255
SOURCE TYPE
Academic Journal
DOC. TYPE
Erratum
ABSTRACT
A correction to the article "A Population-Based Study of the Incidence and Complication Rates of Herpes Zoster Before Zoster Vaccine Introduction" that was published in the November 2007 issue is presented.
ACCESSION #
28841089

 

Related Articles

  • Shingles vaccine supply secured.  // New Zealand Doctor;2/26/2014, p9 

    The article reports that new shipment of Zostavax vaccine, has been received by New Zealand, before the old stock expired on November 5, 2013.

  • Shingles vaccination uptake varies regionally. Turnbull, Alex // Independent Nurse;5/4/2015, p7 

    No abstract available.

  • Risk for Zoster from the Vaccine in Immunosuppressed Persons. Kuritzky, Louis // Internal Medicine Alert;8/15/2012, Vol. 34 Issue 15, p119 

    The article presents information on the risk of herpes zoster vaccines (ZOS) in context to the presence of live virus during the treatment to the immunosuppressed persons.

  • Reply to Arroyo. Schmader, Kenneth E.; Levin, Myron J.; Keay, Susan; Chan, Ivan S. F.; Annunziato, Paula W.; Parrino, Janie // Clinical Infectious Diseases;Sep2012, Vol. 55 Issue 6, p889 

    A response by K.E. Schmader, M.J. Levin and J.W. Gnann to a letter to the editor about their article "Efficacy, safety, and tolerability of herpes zostervaccine in persons aged 50-59 years," in a 2012 issue is presented.

  • Unsettled Issues of Zostavax Vaccine. Arroyo, Julio C. // Clinical Infectious Diseases;Sep2012, Vol. 55 Issue 6, p889 

    A letter to the editor is presented in response to the article "Efficacy,safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years," by K.E. Schmader, M.J. Levin and J.W. Gnann in a 2012 issue.

  • IS HERPES ZOSTER VACCINE FREE FOR NURSES OR WILL WE HAVE TO PAY? Piggott, Carol // Nursing Standard;4/30/2014, Vol. 28 Issue 35, p35 

    A letter to the editor is presented in response to an article by Dinah Gould in the April 16, 2014 issue that was concerned with a varicella zoster virus vaccine.

  • Zoster vaccine is safe and well-tolerated.  // Australian Journal of Pharmacy;Aug2012, Vol. 93 Issue 1107, p93 

    The article presents information on a study related to the safety of using zoster vaccine in adults.

  • INVESTIGATIONAL VACCINE FOR HERPES ZOSTER SHOWS PROMISE.  // Medical Economics;5/25/2015, Vol. 92 Issue 10, p15 

    The article discusses the results of a phase 3 international trial published in the April 2015 issue of the "New England Journal of Medicine" which reveal that an investigational vaccine for herpes zoster (HZ) provided notable benefit to patients 50 and older.

  • Large study shows no serious reactions to shingles vax.  // Reactions Weekly;5/12/2012, Issue 1401, p2 

    The article reports on a postmarketing U.S. study published online in the "Journal of Internal Medicine" which found that the herpes zoster vaccine is generally safe and well tolerated.

  • Response to Dr Clearkin. Williams, G; Olson, J A // Eye;Dec2014, Vol. 28 Issue 12, p1523 

    A reply to the letter to the editor in response to an article about the implementation of shingles vaccine in Great Britain is presented.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics